Researchers to Present Results From Two VIRxSYS HIV Studies at the 6th International AIDS Society Meeting

GAITHERSBURG, MD--(Marketwire - Jun 28, 2011) - VIRxSYS Corporation today announced that data from two HIV studies will be presented at the 6^th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, July 17 to 20, 2011, in Rome. The two studies that organizers of the prestigious conference, the largest of the year for HIV research, have accepted are:

A lentiviral vector HIV vaccine candidate protects macaques from high dose SIV intrarectal challenge: vaccine responders achieve complete and sustained control of viral load, fully preserved CD4 counts, reduction of proviral DNA in viral reservoirs, and survival advantage; and

Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV-1 env gene influences HIV replication and evolution in vivo.

The presentations will provide updates to previously reported studies on VIRxSYS novel therapeutic vaccine candidate VRX1273 and its phase II investigational therapy VRX496 cell based RNA immuno-therapy, respectively. The Company previously demonstrated marked and sustained control of SIV replication in the rhesus macaque model with its lentiviral vector-based vaccine VRX1273, and excellent short and long term safety data in humans with VRX496.

Data from the VRX1273 study will also be discussed at a satellite symposium, NAPWAs' Treatment Horizons: Pathways to a Functional Cure, Tuesday, July 19^th from 7am to 8:30am, CEST.

VIRxSYS Corporation is a biotechnology company with platform technologies focused on the development of novel therapies for serious human diseases. The Company's proprietary platforms include: (i) lentiviral vectors as vaccines and curative gene delivery vehicles to the core of human cells, and (ii) RNA trans-splicing for the repair and reprogramming of genes.

More information can be found at www.virxsys.com.